PROTHROMBIN G20210A

Clinical trials for PROTHROMBIN G20210A explained in plain language.

Never miss a new study

Get alerted when new PROTHROMBIN G20210A trials appear

Sign up with your email to follow new studies for PROTHROMBIN G20210A, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet recruiting 1

New shot aims to prevent dangerous clots in High-Risk patients

Disease control Recruiting now

This early-stage study tests a single injection of CITY-FXI, a drug designed to lower a clotting factor in the blood. It includes healthy adults and those with Factor V Leiden or prothrombin G20210A mutations, which increase clot risk. The main goal is to check safety and how the…

Matched conditions: PROTHROMBIN G20210A

Phase: PHASE1 • Sponsor: City Therapeutics • Aim: Disease control

Last updated May 26, 2026 09:24 UTC

PROTHROMBIN G20210A

Get alerted when new PROTHROMBIN G20210A trials appear

New shot aims to prevent dangerous clots in High-Risk patients